|
Iranian Journal of Pharmacology & Therapeutics, Vol. 5, No. 1, 2006, pp. 55-59 Research Article A Study on Clinical Efficacy of Lepidium sativum Seeds in Treatment of Bronchial AsthmaArchana N. Paranjape, Anita A. Mehta Current Author Addresses Archana N. Paranjape. Dept. of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, Gujarat, India. Received November 20, 2005; Revised June 29, 2006; Accepted July 5, 2006 Code Number: pt06009 ABSTRACT The present investigation was carried out to determine the efficacy and safety of Lepidium sativum (L. sativum) (Garden Cress, Fam: Cruciferae) in patients of bronchial asthma. L. sativum seed powder was given at a dose of 1 gm thrice a day orally to 30 patients of either sex in the range of 15-80 years with mild to moderate bronchial asthma without any concurrent medication. The respiratory functions (FVC, FEV1, FEF25-75% and MVV) were assessed using a spirometer prior to and after 4 weeks of treatment. Efficacy of the drug in improving clinical symptoms and severity of asthmatic attacks was evaluated by interviewing the patient and by physical and hematological examination at the end of the treatment. 4 weeks treatment with the drug showed statistically significant improvement in various parameters of pulmonary functions in asthmatic subjects. Also significant improvement was observed in clinical symptoms and severity of asthmatic attacks. None of the patient showed any adverse effect with L. sativum. The results of the present study suggest the usefulness of L. sativum seeds in patients with bronchial asthma. Keywords: Bronchial asthma, Lepidium sativum, Pulmonary function tests Lepidium sativum (L. sativum) (Garden Cress, Fam: Cruciferae) is an annual erect herbaceous plant, growing up to 30 cm. It is a well known culinary herb and the leaves are widely used as a garnish and are consumed raw in salads. The plant is known to possess varied medicinal properties. Leaves of this plant are diuretic and gently stimulant. The seeds are aperient, diuretic, tonic, demulcent, aphrodisiac, carminative, galactagogue and emmenagogue [1]. The seeds are rubefacient and are applied as a poultice for hurts and sprains [2]. The plant also shows teratogenic effect [3] and antiovulatory properties [4-7]. The root is used in the treatment of secondary syphilis and tenesmus [2]. A preliminary pharmacological study on seeds of L. sativum has suggested the presence of cardioactive substance and is shown to have probable action through adrenergic mechanisms [8]. The aqueous extract of L. sativum seeds has been reported to exhibit a potent hypoglycaemic activity in normal and streptozotocin induced diabetic rats [9]. Aqueous extract of L. sativum was found to have antihypertensive and diuretic effect when studied both in normotensive and spontaneously hypertensive rats [10]. The effectiveness of this plant in treatment of bronchial asthma, hiccups, cough with expectoration and bleeding piles has been reported [2]. Seeds of L. sativum are prescribed by many Ayurvedic practitioners in bronchial asthmatic patients. However, no scientific studies are so far carried out to investigate the efficacy of L. sativum in the treatment of bronchial asthma. The present study was undertaken to investigate the antiasthmatic activity of dried seeds of L. sativum in Indian asthmatic patients. Materials and MethodsDried seeds of L. sativum obtained from a commercial supplier were identified and authenticated by Dr.Daniel, Dept. of Botany, M.S.University, Vadodara, Gujarat, India and a voucher specimen was deposited in BARO the herbarium of department of Botany, M.S.University, Vadodara. Dried seeds were powdered and used for the study. An open label, noncomparative clinical study was carried out on patients of either sex, having mild to moderate bronchial asthma and visiting Out Patient Department of Govt. Ayurvedic Hospital, Vadodara, India. The protocol for carrying out the clinical study was approved by Director, Dept. of Ayurveda and Homeopathic Medicine, Govt. of Gujarat, India and also by the institutional ethics committee for the clinical study. Informed Consent was obtained from all patients enrolled in the study. All patients in the age range of 15-80 years having mild to moderate bronchial asthma as diagnosed by their clinical history; commonly observed symptoms of bronchial asthma (dyspnoea, wheezing, tightness in chest, cough etc.) and physical examination were enrolled in the study. Patients having breathlessness due to cardiovascular disorders were excluded. Patients having very severe bronchial asthma (Peak Expiratory flow rate (PEFR) < 20% and Forced Expiratory volume in 1 second (FEV1) < 20% of predicted value) were not enrolled. Patients below age of 15 years and pregnant women were excluded. Patients with disorders such as pulmonary tuberculosis and cardiovascular disorders etc. were also not enrolled in the study. In the patients satisfying the inclusion and exclusion criteria, baseline characteristics were measured and clinical and family history was recorded. Details of duration of bronchial asthma, other diseases present and concomitant medication taken were recorded. Patients were given finely powdered dried seeds at a dose of 1g thrice a day for 4 weeks and were advised to take it orally with water. For patients taking concurrent medication for bronchial asthma, details of the drugs used and their dosages were collected before starting the treatment with L. sativum and at the end of the study. General physical examinations which include temperature, heart rate, blood pressure and respiratory rate were measured before start of the treatment and at every week after start of the treatment. hematological examinations which include Haemoglobin estimation, total leukocyte count, differential leukocyte count and erythrocyte sedimentation rate were carried out before start of the treatment and at the end of 4 weeks of treatment. Patients were given medication supply of 1 week and were asked to report every week. At every weekly visit, patients were asked for occurrence of untoward effect if any and improvement in the symptoms observed. Symptom score was measured for all commonly observed symptoms of bronchial asthma i.e. dyspnoea, wheezing, cough and chest tightness before starting the treatment and at the end of 4 weeks of treatment. Score was graded as 3, 2, 1 and 0 for presence of severe, moderate, mild and absence of any symptom respectively [11]. Grades were given by interviewing the patient and by physical examination. Evaluation of lung functions was done with the help of computer aided spirometer. Spirometry was performed before starting the treatment with L. sativum and at the end of 4 weeks of treatment. The values were expressed as mean ± Standard error of Means (S.E.M.) Statistical significance of the differences in parameters before and after treatment was calculated using Students paired t-test. p < 0.05 was considered to be significant. Results Demographic Profile Thirty four patients satisfying inclusion and exclusion criteria were enrolled in the study. However, 4 patients discontinued the study in between due to unknown reasons. 30 patients completed the total 4 weeks of study. Demographic profile of the patients enrolled is shown in Table 1.
Effect of L. Sativum on Physical Parameters and Hematological Profile of the Asthmatic Patients General physical parameters like temperature, heart rate, respiratory rate, and blood pressure were recorded before, every week and at the end of 4 weeks of treatment with L. sativum. No significant change was observed in any of these parameters by treatment with L. sativum (Table 3). Also hematological parameters were not changed markedly with L. sativum except Erythrocyte sedimentation rate (ESR). ESR was significantly reduced by treatment with L. sativum (Table 4). Effect of L. Sativum on Commonly Observed Symptoms of Bronchial AsthmaIn the present study, L. sativum was found to significantly improve the commonly observed symptoms of bronchial asthma. Symptom score of all symptoms was significantly reduced by L. sativum (Fig 1).
Effect of L. Sativum on Lung Function Parameters of the Asthmatic Patients In the present study, L. sativum caused highly significant increase in Forced Vital Capacity (FVC) (p<0.001) and Forced Expiratory volume in 1 sec (FEV1) (p<0.01) of the patients (Fig 2). Mean % increase found in FVC was 32.92 ± 10.07 % and in FEV1 was 35.81 ± 8.32 % (Table 5). However, no significant change was observed in ratio of FVC and FEV1 (FVC/FEV1%) by L. sativum (Fig 3). In the present study, L. sativum also significantly increased Peak Expiratory Flow Rate (PEFR) (p < 0.01) of the patients (Fig 4). Mean % increase found in PEFR was 43.58 ± 13.56 % (Table 6). Forced Expiratory Flow between 25 and 75 % (FEF25-75%), FEF25%, and FEF50% were also significantly increased by L. sativum. However FEF75% was not significantly increased with L. sativum (Fig 5). Mean % increases found in these parameters were 42 ± 13.48 %, 43.87 ± 13.37 %, and 43.21 ± 13.28 % and 38.49 ± 14.80 % respectively (Table 6). Maximum voluntary ventilation (MVV) was also significantly increased by L. sativum (Fig 6). Mean % increase found in MVV was 18.23 ± 6.59 % (Table 6). DiscussionBronchial asthma is one of the commonest respiratory illnesses characterized by increased responsiveness of the tracheobronchial tree to a multiplicity of stimuli. It manifests physiologically by a widespread narrowing of airways and clinically by paroxysms of dyspnoea, cough and wheezing [12]. Significant decrease in all commonly observed symptoms of bronchial asthma by L. sativum in the present study suggests the effectiveness of this drug in improving the symptoms associated with asthma. Apart from the symptoms, decrease in ESR observed by L. sativum in the present study also indicates the beneficial effect in asthmatic patients since ESR is found to be higher in many patients of bronchial asthma. Eosinophils are considered to be the major inflammatory cells in asthma as they damage the epithelial cells lining in bronchial tree [13, 14]. In present study, eosinophil count was not found to be significantly decreased by L. sativum as most of the patients were found to have normal eosinophil count during admission in the trial. However, in patients with eosinophil count higher than normal, treatment with L. sativum was found to reduce the eosinophil count to normal values. Along with the symptoms, measurement of lung function by spirometer provides
direct assessment of the asthma severity and the effect of drug in treatment of
this disease. FVC (Forced Vital Capacity) is clinically useful as an index of
lung functions. FEV1 (forced expired volume in one second) is a
useful measure of how quickly full lungs can be emptied and is a best single
measure of lung function for assessing airflow limitation or asthma severity [15]. In the present study, L. sativum was found
to significantly increase FVC and FEV1 indicating its usefulness in
reducing asthma severity. The FEV1/FVC ratio is expressed as a
percentage, and a normal young individual is able to forcibly expire at least
80% of his/her vital capacity in one second. A ratio under 70% suggests
underlying obstructive physiology. However, in present study no significant
change was observed in ratio of FVC and FEV1 (FVC/FEV1%).
This may be because of increase in both FVC and FEV1 by L.
sativum. FEF25-75% is the average expired flow over the middle
half of the FVC manoveure and is regarded as a more sensitive measure of small
airways narrowing than FEV1. FEF25-75% was found to be increased
significantly by L. sativum. L. sativum also significantly
increased Peak Expiratory Flow Rate (PEFR) which is reduced by more than 40 %
in asthmatic patients, where the resistance of the airways is increased owing
to bronchial constriction. Response to asthma treatment is usually accompanied
by an increase in PEFR and a decrease in its variability [15].
Statistically significant increase in lung function parameters by L. sativum
suggests the effectiveness of this drug in the treatment of bronchial asthma.
Thus, in the present clinical study on L. sativum, all patients were found to show the trend towards decrease in severity of symptoms of asthma and improvement in lung function parameters. Thus considering the efficacy and convenience of oral administration and easy availability, this drug appears to have good future in treatment of asthma. Moreover none of the patients showed any adverse effect in dose used and no change was observed in general physical parameters and hematological profile of the patients suggesting good tolerability of this drug. However, detailed experimental studies are required to investigate its mechanism of action. AcknowledgementsAuthors are thankful to Govt. Ayurvedic Hospital, Vadodara and Sanjiv Hospital, Vadodara for extending their help to perform the clinical studies. References
The following images related to this document are available:Photo images[pt06009f2.jpg] [pt06009f5.jpg] [pt06009f6.jpg] [pt06009f4.jpg] [pt06009f3.jpg] [pt06009f1.jpg] |
|